Long-term complications of platinum-based chemotherapy in testicular cancer survivors

Medical Oncology

Volumn 24, Issue 2, 2007, Pages 175-181

  Oh, J H ^a   Baum, D D ^a   Pham, S ^a   Cox, M ^a   Nguyen, S T ^b   Ensor, J ^a   Chen, I ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

Carboplatin; Cardiovascular; Cisplatin; Complications; Germ cell tumor; Non seminoma; Platinum compounds; Seminoma; Survivorship; Testicular cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PLATINUM; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; BLOOD PRESSURE MEASUREMENT; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVOR; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; INTERVIEW; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SURVIVAL TIME; TESTIS CANCER; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; CORONARY ARTERY DISEASE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RISK FACTORS; SURVIVORS; TESTICULAR NEOPLASMS; TESTOSTERONE;

EID: 36249006939     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02698037     Document Type: Review

References (27)

1. Ries LAG, et al. (eds). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site, 2006.
2. Bols GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337(4):242-253.
3. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990;8(11):1777-1781.
4. Einhorn LH. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981;41(9 Pt 1):3275-3280.
5. Hamilton CR, Bliss JM, Horwich A. The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol 1989;25(2):185-189.
6. Aass N, Fossa SD, Aas M, Lindegaard MW. Renal function related to different treatment modalities for malignant germ cell tumours. Br J Cancer 1990;62(5):842-846.
7. Schilsky RL, Barlock A, Ozols RF. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treatment Reports 1982;66(9):1767-1769.
8. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981;95(3):288-282.
9. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14(11):2923-2932.
10. Meinardi MT. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18(8):1725-1732.
11. Gietema JA, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992;16(9):709-715.
12. Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992;10(9): 1386-1389.
13. Nichols CR, et al. No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol 1992;10(5):760-765.
14. Huddart RA, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21(8):1513- 1523.
15. van den Belt-Dusebout, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24(3): 467-475.
16. Chobanian A, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003;289:2560-2571.
17. National Center for Health Statistics. Health, United States, 2004 with Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; 2004:238.
18. Lethbridge-Cejku M, Rose D, Vickerie J. Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2004. National Center for Health Statistics. Vital and Health Stat Series No. 10(228):17.2006.
19. Kohn S, et al. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct Pathol 1997;21(3):289-299.
20. Nuver J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005;23(36):9130- 9137.
21. Nuver J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004;40:701-706.
22. Lackner J, et al. Treatment of testicular cancer: influence on pituitary-gonadal axis and sexual function. Urology 2005;66(2): 402-406.
23. Huddart R A, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005;93(2):200-207.
24. Pectasides D, et al. Testicular function in patients with testicular cancer treated with bleomycinetoposide-carboplatin (BEC(90)) combination chemotherapy. Eur Urol 2004;45(2):187-193.
25. Nord C, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003;44(3): 322-328.
26. Wiechno PJ, et al. Hormonal status and the quality of life of cancer survivors J Clin Oncol 2006;24(18S):4548.
27. Nuver J, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005;23(16):3718-3725.